Fieldpoint Private Securities LLC Sells 844 Shares of Humana Inc. (NYSE:HUM)


Share on StockTwits

Fieldpoint Private Securities LLC lessened its position in Humana Inc. (NYSE:HUM) by 92.5% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 68 shares of the insurance provider’s stock after selling 844 shares during the period. Fieldpoint Private Securities LLC’s holdings in Humana were worth $29,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the business. Norges Bank purchased a new position in shares of Humana during the fourth quarter valued at about $601,429,000. FMR LLC lifted its stake in shares of Humana by 14.0% in the fourth quarter. FMR LLC now owns 9,267,673 shares of the insurance provider’s stock worth $3,802,248,000 after buying an additional 1,136,161 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Humana by 7.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 9,989,308 shares of the insurance provider’s stock worth $4,098,313,000 after purchasing an additional 656,606 shares in the last quarter. Amundi Pioneer Asset Management Inc. raised its position in Humana by 147.9% in the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 567,827 shares of the insurance provider’s stock worth $232,963,000 after buying an additional 338,754 shares during the last quarter. Finally, Ceredex Value Advisors LLC raised its holdings in shares of Humana by 104.4% during the fourth quarter. Ceredex Value Advisors LLC now owns 628,440 shares of the insurance provider’s stock valued at $258,220,000 after purchasing an additional 321,038 shares during the last quarter. Hedge funds and other institutional investors own 91.90% of the company’s stock.

HUM has been the topic of several analyst reports. Argus lifted their price target on shares of Humana from $430.00 to $450.00 and gave the stock a “buy” rating in a research note on Wednesday, January 6th. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell lifted their price target on shares of Humana from $496.00 to $510.00 and gave the company a “buy” rating in a report on Thursday, April 29th. Royal Bank of Canada upgraded Humana from a “sector perform” rating to an “outperform” rating and increased their target price for the company from $429.00 to $479.00 in a research report on Monday, January 4th. Citigroup lifted their price target on Humana from $496.00 to $510.00 in a research report on Thursday, April 29th. Finally, Mizuho boosted their price objective on shares of Humana from $462.00 to $480.00 and gave the company a “buy” rating in a research report on Thursday, April 29th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and eleven have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $469.45.

In other Humana news, Director Jorge S. Mesquita purchased 375 shares of the stock in a transaction on Monday, March 8th. The shares were bought at an average price of $403.37 per share, for a total transaction of $151,263.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Christopher H. Hunter sold 5,156 shares of the firm’s stock in a transaction that occurred on Thursday, April 29th. The shares were sold at an average price of $443.76, for a total value of $2,288,026.56. Following the completion of the sale, the insider now directly owns 8,653 shares in the company, valued at $3,839,855.28. The disclosure for this sale can be found here. Insiders have sold a total of 36,389 shares of company stock worth $14,097,808 in the last ninety days. Corporate insiders own 0.42% of the company’s stock.

Shares of NYSE:HUM opened at $450.60 on Tuesday. The business has a 50-day moving average price of $424.16 and a 200-day moving average price of $410.07. The stock has a market cap of $58.13 billion, a price-to-earnings ratio of 14.44, a PEG ratio of 1.57 and a beta of 0.86. Humana Inc. has a 52-week low of $364.77 and a 52-week high of $474.70. The company has a quick ratio of 1.81, a current ratio of 1.81 and a debt-to-equity ratio of 0.38.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, April 28th. The insurance provider reported $7.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $7.21 by $0.46. The company had revenue of $20.67 billion during the quarter, compared to the consensus estimate of $20.42 billion. Humana had a net margin of 5.58% and a return on equity of 22.74%. The firm’s quarterly revenue was up 9.2% on a year-over-year basis. During the same period in the previous year, the firm posted $5.40 earnings per share. As a group, equities analysts anticipate that Humana Inc. will post 18.66 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 30th. Shareholders of record on Wednesday, June 30th will be given a $0.70 dividend. The ex-dividend date is Tuesday, June 29th. This represents a $2.80 annualized dividend and a yield of 0.62%. Humana’s dividend payout ratio is presently 15.67%.

Humana Profile

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Recommended Story: Why is the ex-dividend date different from the record date?

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.